Session Details

Workshop 1 - NAVRMA Joint Session Veterinary medicine in developing cell-based therapies and bioengineering approach for human clinical use
Friday, September 13, 2019 10:45 AM - 12:15 PM
Plenary Hall
Co-Chairs:
Daniel Weiss, MD, PhD, University of Vermont, USA
Tracy Webb, DVM, PhD, Colorado State University, USA

Speakers:
Companion animal models scaffold to regenerative medicine therapeutics in humans
Andrew Hoffman, DVM, DVSc, School of Veterinary Medicine, University of Pennsylvania, USA
Learning objectives:
•      Review of Companion Animal Models
•      Review of Process of Enrolling Companion Animals
•      Review of Clinical Trials of Stem Cells in Companion Animals

Cell & Gene Therapies for Joint Disease and Cartilage Repair Using the Horse as a Model for Human Disease
Kyla Ortved, DVM, PhD, University of Pennsylvania School of Veterinary Medicine, USA
Learning Objectives:
•      Evaluate current MSC-based therapies for resurfacing cartilage and treating osteoarthritis.
•      Discuss different gene therapy options for joint disease.
•      Summarize the clinical use of gene and cell therapies for joint disease in the horse.

Equine models of joint disease for the investigation of cell-based therapies
Aimee Colbath, VMD, PhD, DACVS-LA, Michigan State University College of Veterinary Medicine, USA
Learning objectives:
•      Describe why the horse is an ideal model for testing cell-based therapies for joint disease
•      Describe equine surgical, experimental models of osteoarthritis appropriate for testing cell-based therapies
•      Describe non-surgical, experimental models of joint inflammation appropriate for testing of cell-based therapies

How naturally occurring disease models in dogs and cats inform human clinical trials
Dori Borjesson, BA, DVM, MPVM, PhD, UC Davis School of Veterinary Medicine, USA
Learning objectives:
•      Understand the role of naturally occurring models of dog and cat disease to inform human cell therapy clinical trials
•      Define some best practices for working with veterinarians and clinical trials in cell therapy arena
•      Understand how data including safety, efficacy, biomarker discovery and even mechanism of action studies performed in dogs and cats can be leveraged at the FDA